| Outcome Measures: |
Primary: Percentage of patients in each group who had at least a 20% decrease in one or more nodules of more than 2 cm at 2 years., Size : The reduction of TN will be evaluated by thyroid ultrasonography. The operator will be the same throughout the follow-up and in each center, with an evaluation every 6 months. A measurement and precise analysis of the TN will be performed. If a TIRADS 4 or 5 classification is described , a new fine-needle aspiration cytology will be performed. A final thyroid ultrasonography evaluation will be performed at 2 years in order to allow the comparison of TN sizes from the pre-inclusion period to the final period., 24 months | Secondary: Percentage of thyroid surgery observed in each group at 2 years., Record the number of thyroid surgeries performed after inclusion for 2 years, 24 months after treatment initiation|Number of new TN (≥ 10mm) after 2 years of follow-up, Detection of new TN (≥ 10mm) by thyroid ultrasonography. The operator will be the same throughout the follow-up and in each center, Baseline and 24 months after treatment initiation|Change between percentage of metabolic syndrome before and after treatment according to the NCEP ATP III definition, Central or abdominal obesity (measured by waist circumference): * Men - greater than 40 inches (102 cm) * Women - greater than 35 inches (88cm) Triglycerides plasmatic levels greater than or equal to 150 mg/dL (1.7 mmol/L) HDL cholesterol : * Men - Less than 40 mg/dL (1.03 mmol/L) * Women - Less than 50 mg/dL (1.29 mmol/L) Blood pressure greater than or equal to 130/85 mm Hg Fasting glucose greater than or equal to 110 mg/dL (6.1 mmol/L), Baseline, every 6 months after treatment initiation until 24 months|Proportion of subjects with improvement of the HOMA-IR index, The HOMA index will be measured after calculation the ratio between the \[fasting plasma insulin (Mu / L) X Fasting plasma glucose (mmol / l)\] / 22.5, Baseline, every 6 months after treatment initiation until 24 months|Proportion of subjects with improvement of adipokine concentrations, Among the adipokines, we will measure the plasmatic Leptin, Adiponectin and Vifastin levels, Baseline and 24 months after treatment initiation|Plasmatic thyroid hormon levels, these dosages will allow us to evaluate the changes in the functioning of the nodular thyroid gland during follow-up under either treatment, Baseline, every 6 months after treatment initiation until 24 months|Percentage of IGF-1 receptor expression in thyroid tissues after TN surgery, The analysis of the tissue expression of IGF1 receptors will be performed on thyroid samples after surgery if performed. One sample will be frozen and another will be included in paraffin for further analysis. IGF1 receptors are involved in the insulin and glucose metabolism signaling pathways. Analysis of their expression could help us to understand the possible links between insulin resistance and thyroid nodule., through study completion, an average of 1 year|Percentage of adiponectin receptor expression in thyroid tissues after TN surgery, The analysis of the tissue expression of adiponectin receptor will be performed on thyroid samples after surgery if performed. One sample will be frozen and another will be included in paraffin for further analysis. Adiponectin receptor are involved in the insulin and glucose metabolism signaling pathways. Analysis of their expression could help us to understand the possible links between insulin resistance and thyroid nodule., through study completion, an average of 1 year
|
| Locations: |
CHU Bordeaux, Bordeaux, 33000, France|CHU Limoges, Limoges, 87042, France|University Hospital Center of Guadeloupe, Pointe-à-Pitre, 97159, Guadeloupe|CHU de la Réunion, Saint-Pierre, 97400, Réunion
|
